Regentis Biomaterials Ltd. (NYSE American: RGNT) is making strides in orthopedic medicine with its cell-free hydrogel implant, GelrinC, designed to repair knee cartilage damage in a single, approximately 10-minute procedure. The company aims to fill a significant gap in the U.S. market, where roughly 472,500 arthroscopic knee procedures each year involve cartilage damage, yet no off-the-shelf regenerative solution capable of restoring hyaline-like cartilage is currently approved.
Unlike traditional microfracture procedures or complex cell-based therapies that often require multiple surgeries and lengthy preparation, GelrinC is a ready-to-use implant that supports native cartilage regeneration over time. The product has already received CE Mark approval in Europe and is advancing through a pivotal U.S. FDA trial that is now more than 50% enrolled. Regentis is also preparing for potential commercialization, highlighted by a newly patented solvent-free manufacturing process that increased production yield by 400%, alongside ongoing efforts to build physician adoption infrastructure across Europe.
The company's technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. This approach aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is available.
For more details, visit the full article at https://ibn.fm/TrCv1. The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT.
